Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.35 |
| ▸ | MOGAT2 | Q3SYC2 | 10/20 | 0.34 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4185999 | 0.89 | KDM4E (0.40) | CYP1A2CYP3A4CYP2C9CYP2C19SCN9A | |
| SCHEMBL4203965 | 0.88 | KDM4E (0.39) | CYP1A2CYP3A4CYP2C9CYP2C19MOGAT2 | |
| SCHEMBL4194889 | 0.79 | ACLY (0.47) | SCN9AMOGAT2ACLYMEN1KMT2A | |
| SCHEMBL4184085 | 0.79 | ACLY (0.47) | SCN9AMOGAT2ACLYMEN1KMT2A | |
| SCHEMBL4706166 | 0.78 | GLO1 (0.35) | SCN9AGLO1MOGAT2MEN1KMT2A | |
| SCHEMBL4193413 | 0.78 | ACLY (0.48) | MOGAT2ACLYMEN1KMT2A | |
| SCHEMBL4190554 | 0.76 | KDM4E (0.40) | SCN9AMOGAT2 | |
| SCHEMBL4201552 | 0.76 | KDM4E (0.40) | CYP3A4CYP2C9CYP2C19SCN9AMOGAT2 | |
| SCHEMBL4198310 | 0.76 | KDM4E (0.44) | ACLYMEN1KMT2A | |
| SCHEMBL4184025 | 0.75 | KDM4E (0.39) | CYP3A4CYP2C9CYP2C19SCN9AMOGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879877-B1 | ANTIMICROBIAL AGENTS | RANBAXY LAB LTD (IN) | 2013-01-02 | — | — | EP | claimed |
| CN-101203504-B | Antimicrobial agents | RANBAXY LAB LTD | 2012-11-14 | — | — | CN | claimed |
| US-8076370-B2 | Antimicrobial agents | RANBAXY LABORATORIES LIMITED (IN) | 2011-12-13 | — | — | US | claimed |
| US-20090215764-A1 | Antimicrobial agents | RANBAXY LABORATORIES LIMITED (IN) | 2009-08-27 | — | — | US | claimed |
| CN-101203504-A | Antimicrobial agents | RANBAXY LAB LTD (IN) | 2008-06-18 | — | — | CN | claimed |
| EP-1879877-B1 | ANTIMICROBIAL AGENTS | RANBAXY LAB LTD (IN) | 2013-01-02 | — | — | EP | disclosed |
| CN-101203504-B | Antimicrobial agents | RANBAXY LAB LTD | 2012-11-14 | — | — | CN | disclosed |
| US-8076370-B2 | Antimicrobial agents | RANBAXY LABORATORIES LIMITED (IN) | 2011-12-13 | — | — | US | disclosed |
| US-20090215764-A1 | Antimicrobial agents | RANBAXY LABORATORIES LIMITED (IN) | 2009-08-27 | — | — | US | disclosed |
| CN-101203504-A | Antimicrobial agents | RANBAXY LAB LTD (IN) | 2008-06-18 | — | — | CN | disclosed |
| EP-1879877-A2 | ANTIMICROBIAL AGENTS | Ranbaxy Laboratories Limited (IN) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006117762-A2 | ANTIMICROBIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215764-A1 | Antimicrobial agents | TUFM, RPS17, HARS1 | CYP1A2 2765/4885CYP3A4 1763/4885CYP2C9 3172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.